2,6-Diallyl-4-benzyloxy-phenol | 205433-80-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2,6-Diallyl-4-benzyloxy-phenol
• 英文别名: 2,6-Diallyl4-benzyloxyphenol；4-phenylmethoxy-2,6-bis(prop-2-enyl)phenol
• CAS: 205433-80-3
• 化学式: C₁₉H₂₀O₂
• 分子量: 280.367
• InChiKey: OMIACGDSWRLDNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-Diallyl-4-benzyloxy-phenol 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 bis(methoxycarbonyl)(phenyliodinio)methanide 、 copper(l) chloride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.08h， 生成
  参考文献：
  名称：

  一种三价碘试剂参与的糖苷化方法

  摘要：

  一种三价碘试剂参与的糖苷化方法，其特征在于，糖基供体(I)在三价碘试剂、过渡金属催化剂存在下活化，然后与受体(II)在酸催化下反应或直接反应，得到糖苷化产物(III)；所述糖基供体(I)中，Gly为糖环上一个或多个羟基被保护基保护的糖基；X为氧、硫或硒原子；R为烷基或芳基；所述受体(II)选自含有一个或多个自由羟基的糖类、醇类、酚类、黄酮类、羧酸类、磷酸类、嘧啶类、嘌呤类、酰胺类、磺酰胺类、胍类、芳基胺类、吲哚类、烯醇硅醚类、硫醇或硫酚类亲核试剂。

  公开号：

  CN116554245A
• 作为产物：
  描述：

  2-Allyl-1-allyloxy-4-benzyloxy-benzene 反应 14.0h， 以77%的产率得到2,6-Diallyl-4-benzyloxy-phenol
  参考文献：
  名称：

  Photochemistry of Substituted 4,4-Dimethoxy-2,5-Cyclohexadienones

  摘要：

  Abstract4,4‐Dimethoxy‐2,5‐cyclohexadienones 9–14 were prepared from the corresponding hydroquinone monomethyl ethers by oxidation with thallium trinitrate in methanol. Irradiation of solutions of 9–13 in methanol with a broad band of UV light centered at 350 nm in a Rayonet reactor afforded 2‐cyclopentenone derivatives 15–19 in moderate to excellent yields, whereas irradiation of 14 in methanol gave phenol 8 along with other unidentified products. Irradiation of 11–14 in benzene yielded substituted phenols. The plausible reaction pathways for the product formation are discussed.

  DOI：

  10.1002/jccs.199800001

文献信息

• Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
  申请人：——

  公开号：US20040024034A1

  公开（公告）日：2004-02-05

  Compounds represented by the following (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

  以下化合物（I）及其药用可接受的盐、溶剂化合物和水合物，其中R1是未取代或取代的芳基、杂环芳基、环烷基、芳基-烷基、杂环芳基-烷基或环烷基-烷基，R2是H、烷基或卤代烷基，聚亚甲基链（II）饱和或可能含有碳-碳双键，n为2、3、4，W为O或S，Y是未取代或取代的苯基、萘基或1,2,3,4-四氢萘基，R3是H、烷基或卤代烷基。R4是H、烷基、卤代烷基或取代或未取代的苄基，用于调节过氧化物酶体增殖物激活受体，特别是在糖尿病治疗中是有用的。
• Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
  申请人：Brooks Alisa Dawn

  公开号：US20050250825A1

  公开（公告）日：2005-11-10

  Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (H), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl, R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

  以下结构式（I）所代表的化合物及其药学上可接受的盐、溶剂化合物和水合物，其中R1是未取代或取代的芳基、杂环芳基、环烷基、芳基-烷基、杂环芳基-烷基或环烷基-烷基，R2是氢、烷基或卤代烷基，聚亚甲基链（H）是饱和的或可能含有碳-碳双键，而n为2、3、4，W为O或S，Y为未取代的苯基、萘基或1、2、3、4-四氢萘基，R3是氢、烷基或卤代烷基，R4是氢、烷基、卤代烷基或取代或未取代的苄基，可用于调节过氧化物酶体增殖物激活受体，特别是用于治疗糖尿病。
• 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders
  申请人：——

  公开号：US20040092596A1

  公开（公告）日：2004-05-13

  A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

  一类2-芳氧基-2-芳基脂肪酸是PPAR alpha和/或gamma的有效激动剂，因此可用于治疗、控制或预防非胰岛素依赖性糖尿病（NIDDM）、高血糖、脂质代谢异常、高脂血症、高胆固醇血症、高三酰甘油血症、动脉粥样硬化、肥胖症、血管再狭窄、炎症和其他PPAR alpha和/或gamma介导的疾病、疾病和病况。
• 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
  申请人：Adams D. Alan

  公开号：US20060122242A1

  公开（公告）日：2006-06-08

  A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

  一类2-芳氧基-2-芳基脂肪酸是一种强效PPAR alpha和/或gamma激动剂，因此可用于治疗、控制或预防非胰岛素依赖性糖尿病（NIDDM）、高血糖、失调脂质代谢、高脂血症、高胆固醇血症、高三酰甘油血症、动脉粥样硬化、肥胖症、血管再狭窄、炎症和其他PPAR alpha和/或gamma介导的疾病、疾病和状况。
• OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS
  申请人：Brooks Dawn Alisa

  公开号：US20080146631A1

  公开（公告）日：2008-06-19

  Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl, R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a preoxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

  以下结构式（I）所代表的化合物，以及其药学上可接受的盐、溶剂合物和水合物，其中R1为未取代或取代的芳基、杂环芳基、环烷基、芳基烷基、杂环芳基烷基或环烷基烷基，R2为H、烷基或卤代烷基，多亚甲基链（II）为饱和或含有碳-碳双键，n为2、3、4，W为O或S，Y为未取代或取代的苯基、萘基或1,2,3,4-四氢萘基，R3为H、烷基或卤代烷基，R4为H、烷基、卤代烷基或取代或未取代的苄基。这些化合物对于调节前线体增生激活受体特别是在糖尿病治疗中是有用的。